Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Hisamitsu’s Transdermal Schizophrenia Med Hits Primary Endpoint: US PIII
Hisamitsu Pharmaceutical said on January 31 that its investigational transdermal schizophrenia treatment HP-3070 hit the primary endpoint in a PIII clinical trial in the US. The Japanese patch drug powerhouse plans US filing based on these data in FY2018. The…
To read the full story
Related Article
- Hisamitsu Starts PIII Trial of Transdermal Schizophrenia Treatment in US
September 6, 2016
BUSINESS
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable
July 31, 2026
- Astellas Expands AI Drug Discovery to TPDs, Engineered Proteins
July 30, 2026
- Regeneron Japan Files First Dual-AAV Therapy for Genetic Hearing Loss
July 30, 2026
- Shionogi’s Xocova Debuts in US for COVID-19 PEP
July 30, 2026
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…